Developing a long-lasting treatment for opioid overdose
IND-enabling development of a long-duration antagonist to treat opioid overdose
['FUNDING_SBIR_2'] · CONSEGNA PHARMA, INC. · NIH-10929469
This study is working on a new version of naloxone, a lifesaving medication for opioid overdoses, that could help keep people safe for up to 24 hours after an overdose, making it easier to manage these situations outside of hospitals.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CONSEGNA PHARMA, INC. (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-10929469 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a new formulation of naloxone, a medication used to reverse opioid overdoses, that lasts significantly longer than current options. The goal is to develop a product that can provide protection against opioid overdose for 12 to 24 hours, addressing the issue of 'renarcotization' where patients can relapse into overdose after initial treatment. By utilizing an innovative design, this research aims to improve the safety and effectiveness of opioid overdose management, especially in non-hospital settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of opioid overdose, including those with opioid use disorder or those using high-potency opioids.
Not a fit: Patients who do not use opioids or are not at risk of opioid overdose may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and longer-lasting treatment option for individuals experiencing opioid overdoses, potentially saving lives.
How similar studies have performed: While naloxone has been widely used, this approach to developing a long-acting formulation is novel and has not been extensively tested in previous research.
Where this research is happening
PITTSBURGH, UNITED STATES
- CONSEGNA PHARMA, INC. — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZANA, LAWRENCE J — CONSEGNA PHARMA, INC.
- Study coordinator: ZANA, LAWRENCE J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.